Сравнение
CagriSema vs. Tirzepatide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
нет данных
2023788-19-2
Молекулярная масса
нет данных
4813 g/mol
Период полувыведения
нет данных
116 h
Последовательность
нет данных
YXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSМеханизм действия
CagriSema
CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
1
4
из них на людях
1
4
Зафиксированные эффекты
2
4
Открытые противоречия
0
1
Задокументированные нежелательные явления
1
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between CagriSema and Tirzepatide?
- CagriSema is classified as "Метаболизм", while Tirzepatide is classified as "Метаболизм". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Tirzepatide: Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mounjaro) and obesity (Zepbound). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CagriSema or Tirzepatide?
- The highest available evidence level is "РКИ на людях" for CagriSema and "РКИ на людях" for Tirzepatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CagriSema and Tirzepatide in Germany and the United States?
- Германия: CagriSema — Не одобрено, Tirzepatide — Рецептурный. США: CagriSema — Не одобрено, Tirzepatide — Рецептурный. These are factual summaries with source and review date on the individual pages.